Search results
Results from the WOW.Com Content Network
The authorities also imported 2 million doses of vaccine from Sinovac, a Chinese company which Thai conglomerate Charoen Pokphand invested in, [7] during February to April 2021. [ 8 ] Likewise, the Thai government also stepped up its attempt to produce its homegrown vaccines amidst criticism, [ 9 ] with "ChulaCov19" and set to begin trials in ...
Reports of a meeting between Pfizer's leader and an activist investor breathed life into the stock, which closed the day more than 3% higher in price. That gain well exceeded the 0.7% increase of ...
Stock indexes closed mostly lower Tuesday as the market delivered a downbeat finish on the final day of another milestone-shattering year on Wall Street. The Dow Jones Industrial Average slipped 0 ...
Shares of Pfizer Inc. (NYSE:PFE) closed higher during Thursday's session, with the company's stock adding around 10% over the past month. Pfizer recently launched a multi-year cost reduction ...
On November 9, 2020, Pfizer announced that BioNTech's COVID-19 vaccine, tested on 43,500 people, was found to be 90% effective at preventing symptomatic COVID-19. [127] The efficacy was updated to 95% a week later. [128] Akiko Iwasaki, an immunologist interviewed by The New York Times, described the efficacy figure as "really a spectacular number."
A preventive measure introduced in May; Thai Chana QR-code before entering a retail premise to track individual customers On 12 January, the World Health Organization (WHO) confirmed that a novel coronavirus was the cause of a respiratory illness in a cluster of people in Wuhan, Hubei, China, who had initially come to the attention of the WHO on 31 December 2019.
Pfizer (PFE) closed the most recent trading day at $46.15, moving -0.09% from the previous trading session. Pfizer (PFE) Stock Sinks As Market Gains: What You Should Know Skip to main content
National regulatory authorities have granted full or emergency use authorizations for 40 COVID-19 vaccines.. Ten vaccines have been approved for emergency or full use by at least one stringent regulatory authority recognized by the World Health Organization (WHO): Pfizer–BioNTech, Oxford–AstraZeneca, Sinopharm BIBP, Moderna, Janssen, CoronaVac, Covaxin, Novavax, Convidecia, and Sanofi ...